Biogen - BIIB Stock Forecast, Price & News

28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 8 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.

28 Wall Street research analysts have issued twelve-month price objectives for Biogen's shares. Their BIIB share price forecasts range from $217.00 to $370.00. On average, they anticipate the company's stock price to reach $305.75 in the next year. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.

Biogen's stock was trading at $239.92 at the start of the year. Since then, BIIB shares have increased by 20.7% and is now trading at $289.52.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our BIIB earnings forecast.

Biogen Inc. (NASDAQ:BIIB) released its earnings results on Tuesday, October, 25th. The biotechnology company reported $4.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.13 by $0.64. The biotechnology company earned $2.51 billion during the quarter, compared to analysts' expectations of $2.47 billion. Biogen had a trailing twelve-month return on equity of 21.31% and a net margin of 27.64%. The firm's quarterly revenue was down 9.7% compared to the same quarter last year. During the same period in the prior year, the business posted $4.77 earnings per share.
Read the conference call transcript.

Biogen issued an update on its FY 2022 earnings guidance on Tuesday, November, 1st. The company provided earnings per share guidance of $16.50-$17.15 for the period, compared to the consensus earnings per share estimate of $16.49. The company issued revenue guidance of $10.00 billion-$10.15 billion, compared to the consensus revenue estimate of $10.00 billion.

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (10.93%), BlackRock Inc. (9.62%), Vanguard Group Inc. (8.27%), State Street Corp (4.79%), Point72 Asset Management L.P. (1.17%) and Price T Rowe Associates Inc. MD (1.07%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos, Stephen A Sherwin and Susan H Alexander.
View institutional ownership trends.

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIIB stock can currently be purchased for approximately $289.52.

Biogen (NASDAQ:BIIB) has a market capitalization of $41.69 billion and generates $10.98 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $19.64 on an earnings per share basis.

The company employs 9,610 workers across the globe.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.